enzh-TWfrdeitjaptrues

Dear Colleagues:

I am writing to you with great sorrow as we watch the coronavirus epidemic continue to impact lives across the globe. Over 500,000 of our fellow human beings have lost their lives to COVID-19, as both the death toll and number of coronavirus cases continues to grow. Here in the United States, the coronavirus cases have greatly increased with much strain on the medical system for many of our states. In addition, there have been many travel restrictions imposed for travel to/from the United States, and many other countries around the globe in response to the COVID-19 pandemic. Our recognition at this time is that it will not be possible to hold the IWWM-11 this year given the large safety concerns and travel restrictions.

Our initial intent was to move the workshop planned for this October in Madrid to 2022. We have succeeded in making this adjustment and have re-booked the WM workshop for the Westin Madrid for October 6-9, 2022. Our website has been adjusted to reflect this postponement. Our local chairs, Professors Ramon Garcia-Sanz and Jesus San Miguel have been very supportive of this adjustment, and we look forward to working with them on the program and being in Madrid as IWWM-12 in 2022.

We are also giving consideration at this time for a smaller WM workshop (IWWM-11) to be held next summer in Boston. This workshop would permit a smaller group of 40 persons to safely attend to discuss emerging data for WM and help in the development of WM treatment guidelines. While we thought this might have been possible for this Fall, the new realities of the COVID-19 crisis, and the feedback from many of our scientific advisors favored a live, but smaller meeting next year.

We will inform you of the details of the revised workshops once they become available. We thank you for all hard work and efforts on behalf of WM patients.

Steve Treon MD, PhD
Chair
WM Workshop Organizing Committee

 

Opening Ceremonies will take place on (date TBD) in the Neptuno room of the Westin Palace Madrid. The ceremony will feature the presentation of the R. Kyle Award and evening lectures.

The Closing Ceremonies will take place on (date TBD) at one of the prestigious art museums in Madrid. The ceremony will feature the presentation of the Waldenstrom Award and evening lectures.

We expect this international Workshop to be as comprehensive as our previous workshop, which included 15 sessions with over 60 technical presentations. Since the IWWM began in 2000, the number of participating international investigators has steadily grown to over 30 countries, and over 6,500 publications including those created and developed from the IWWM Workshops. These publications have been published in the New England Journal of Medicine, Blood, Clinical Lymphoma Myeloma, Haematologica, Journal of Clinical Oncology, Leukemia, Nature, and other top publications.

IWWM-12 will continue the mission to enrich each attendee’s understanding and help foster discoveries and collaborations leading to more effective treatments and ultimately find a cure for Waldenstroms macroglobulinemia.

For more information about IWWM-12, please visit http://waldenstromsworkshop.org/.

For more information about our past WM Workshops, please visit http://wmworkshop.org/.

We look forward to welcoming you to the Workshop!

IWWM-12 Conference Chairs

Ramón García-Sanz, MD, PhD
Hospital Universitario de Salamanca, Salamanca, Spain
Steven Treon, MD, PhD
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Jesús San Miguel, MD
Clinica Universidad de Navarra, Pamplona, Spain
Chris Patterson - Secretariat
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

IWWM-12 Scientific Committee

Ranjana Advani, MD (USA)
Jorge Castillo, MD (USA)
Christian Buske MD, PhD (Germany)
Shirley D’Sa, MD, FRCPath (UK)
Meletios Dimopoulos, MD (Greece)
Zachary Hunter, PhD (USA)
Douglas E Joshua, AM (Australia)
Efstathios Kastritis, MD, PhD (Greece)
Marie Jóse Kersten, MD, PhD (Netherlands)
Véronique Leblond, MD (France)
Roger Owen MD, MRCP, FRCPath (UK)
Bruno Paiva, PhD (Spain)
M. Lia Palomba, MD (USA)
S.T. Pals, MD, PhD (Netherlands)
Constantine Tam, MD, FRACP, FRCPA (Australia)
Alessandra Tedeschi, MD (Italy)
Judith Trotman, MD, FRACP, FRCPA (Australia)
Marzia Varretoni, MD (Italy)

Latest Bing Center News

WM and COVID-19: WMUK Webinar Recordings

WM and COVID-19: WMUK Webinar Recordings

On Friday 19 June, over 260 people joined our webinar, in partnership with Lymphoma Action, to hear our panel of UK experts answer some of the most commonly asked questions around COVID-19 and Waldenstrom's macroglobulinaemia (WM).

Read more..

Ixazomib Plus Rituximab and Dexamethasone Safe, Effective for WM

Ixazomib Plus Rituximab and Dexamethasone Safe, Effective for WM

Ixazomib in combination with subcutaneous rituximab and dexamethasone is feasible and shows promising efficacy and manageable toxicity in patients with relapsed WM.

Read more..

BeiGene Announces European Medicines Agency Acceptance of its Marketing Authorization Application for BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Waldenström’s Macroglobulinemia

BeiGene Announces European Medicines Agency Acceptance of its Marketing Authorization Application for BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Waldenström’s Macroglobulinemia

CAMBRIDGE, Mass. and BEIJING, China, June 18, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that its marketing authorization application ...

Read more..

COVID-19 & Hematologic Malignancies: Patient Experience Update

COVID-19 & Hematologic Malignancies: Patient Experience Update

We are excited to announce this new webcast focusing on the experience of patients undergoing treatment for hematologic malignancies during the COVID-19 era.

Read more..

Dr. Dimopoulos on the Safety of Zanubrutinib in Waldenström Macroglobulinemia

Dr. Dimopoulos on the Safety of Zanubrutinib in Waldenström Macroglobulinemia

Meletios A. Dimopoulos, MD, discusses safety results from the randomized phase 3 ASPEN trial of zanubrutinib (Brukinsa) in patients with Waldenström macroglobulinemia.

Read more..

BTK Inhibitors for the Treatment of Waldenström Macroglobulinemia

BTK Inhibitors for the Treatment of Waldenström Macroglobulinemia

In this video, an international panel of experts sat down with Oncology Learning Network to discuss the 3 Bruton’s tyrosine kinase (BTK) inhibitors active in the treatment of Waldenström macroglobulinemia (WM): ibrutinib, acalabrutinib, and zanubrutinib.

Read more..

ASCO 2020 Virtual Meeting

ASCO 2020 Virtual Meeting

ASCO (American Society of Clinical Oncologists) will hold their 2020 conference online.  As in the past, they provide abstracts online via the conference website.  The scientific program will take place May 29 through May 31.

Read more..

Video from CBS-4 Boston - Dr. Treon discusses COVID-19 / Ibrutinib Trial

Video from CBS-4 Boston - Dr. Treon discusses COVID-19 / Ibrutinib Trial

Researchers say ibrutinib seems to protect those with COVID-19 from lung damage and respiratory distress. They will now conduct a trial to see if the medication can reduce a patient’s need for a ventilator, improve survival and reduce their time in the hospital.

Read more..

COVID-19 Information for Our Patients

COVID-19 Information for Our Patients

The Bing Center would like to share this important information with all of our patients and interested parties to help us all manage through this unprecedented crisis in the best and most productive way possible.

Read more..

Waldenström Macroglobulinemia Specialty Channel

Waldenström Macroglobulinemia Specialty Channel

Welcome to the Oncology Learning Network Waldenstrom Macroglobulinemia Specialty Channel. Here you will find articles dedicated to the research and treatment of WM.

Read more..